EcoR1 Capital LLC Invests $28.67 Million in Zenas BioPharma, Inc. $ZBIO

EcoR1 Capital LLC acquired a new position in Zenas BioPharma, Inc. (NASDAQ:ZBIO) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 789,500 shares of the company’s stock, valued at approximately $28,667,000. Zenas BioPharma makes up 1.3% of EcoR1 Capital LLC’s investment portfolio, making the stock its 15th biggest holding.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quarry LP boosted its holdings in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Zenas BioPharma in the 3rd quarter worth about $30,000. GF Fund Management CO. LTD. purchased a new stake in Zenas BioPharma during the 4th quarter valued at about $38,000. BNP Paribas Financial Markets boosted its holdings in Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after acquiring an additional 1,716 shares during the period. Finally, CWM LLC boosted its holdings in Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares during the period.

Insiders Place Their Bets

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was acquired at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the acquisition, the chief executive officer owned 96,928 shares in the company, valued at $1,636,144.64. This represents a 162.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Hongbo Lu acquired 3,768 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was acquired at an average price of $18.63 per share, with a total value of $70,197.84. Following the acquisition, the director owned 426,736 shares in the company, valued at approximately $7,950,091.68. This trade represents a 0.89% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 273,768 shares of company stock worth $5,150,198. 22.00% of the stock is currently owned by company insiders.

Zenas BioPharma Trading Up 2.1%

Shares of ZBIO stock opened at $18.58 on Thursday. Zenas BioPharma, Inc. has a 1-year low of $8.91 and a 1-year high of $44.60. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94. The business has a 50-day moving average of $19.25 and a 200 day moving average of $24.12. The stock has a market capitalization of $1.17 billion, a PE ratio of -2.19 and a beta of -0.71.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same period in the previous year, the firm posted ($0.80) earnings per share. As a group, sell-side analysts anticipate that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Analyst Ratings Changes

ZBIO has been the subject of several analyst reports. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Guggenheim increased their target price on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 16th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Finally, Morgan Stanley increased their target price on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.29.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.